Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions
Developmental and Epileptic EncephalopathyDravet SyndromeLennox-Gastaut Syndrome
Interventions
DRUG

LP352, bexicaserin

LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube

Trial Locations (28)

3004

Alfred Health, Melbourne

3084

Austin Health, Heidelberg

4101

Queensland Children's Hospital, South Brisbane

10075

Northwell Health, New York

10305

Northeast Regional Epilepsy Group, Staten Island

10532

Boston Children's Health Physicians LLP, Hawthorne

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

27157

Wake Forest University School of Medicine, Winston-Salem

32561

Northwest Florida Clinical Research Group, Gulf Breeze

32803

Advent Health Orlando, Orlando

32806

Research Institute of Orlando, Orlando

33136

University of Miami, Miami

33606

University of South Florida, Tampa

44106

University Hospitals Cleveland Medical Center, Cleveland

49503

Spectrum Health, Grand Rapids

55905

Mayo Clinic, Rochester

60611

Northwestern University Feinberg School of Medicine, Chicago

63110

Washington University School of Medicine, St Louis

72202

Arkansas Children's Hospital, Little Rock

78757

Child Neurology Consultants of Austin, Austin

78758

Austin Epilepsy Care Center, Austin

84132

University of Utah, Salt Lake City

90242

Rancho Los Amigos National Rehabilitation Center (RLANRC), Downey

94158

University of California San Francisco, San Francisco

96817

Hawaii Pacific Neuroscience, Honolulu

97213

Providence Neurological Specialties-East, Portland

98055

University of Washington Valley Medical Center, Renton

98277

OnSite Clinical Solutions LLC, Charlotte

Sponsors
All Listed Sponsors
lead

Longboard Pharmaceuticals

INDUSTRY